BeyondSpring (NASDAQ:BYSI) Stock Price Crosses Below 50 Day Moving Average – Should You Sell?
by Amy Steele · The Cerbat GemBeyondSpring Inc. (NASDAQ:BYSI – Get Free Report)’s stock price crossed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $1.60 and traded as low as $1.46. BeyondSpring shares last traded at $1.49, with a volume of 9,890 shares changing hands.
Analyst Ratings Changes
Separately, Weiss Ratings restated a “sell (d+)” rating on shares of BeyondSpring in a report on Friday, March 27th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.
View Our Latest Stock Report on BeyondSpring
BeyondSpring Price Performance
The business has a 50-day moving average of $1.60 and a two-hundred day moving average of $1.72. The company has a market cap of $61.27 million, a P/E ratio of -9.93 and a beta of 0.42.
BeyondSpring (NASDAQ:BYSI – Get Free Report) last posted its quarterly earnings data on Wednesday, March 25th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.49.
Institutional Trading of BeyondSpring
A hedge fund recently raised its stake in BeyondSpring stock. Geode Capital Management LLC boosted its stake in shares of BeyondSpring Inc. (NASDAQ:BYSI – Free Report) by 951.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 256,212 shares of the company’s stock after purchasing an additional 231,844 shares during the period. Geode Capital Management LLC owned approximately 0.64% of BeyondSpring worth $603,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 40.29% of the company’s stock.
About BeyondSpring
BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.
The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.